A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer

Investigational New Drugs

Volumn 32, Issue 6, 2014, Pages 1123-1133

  Valtorta, Silvia ^a,b   Nicolini, Gabriella ^c   Tripodi, Farida ^c,d   Meregalli, Cristina ^c   Cavaletti, Guido ^c   Avezza, Federica ^c   Crippa, Luca ^e   Bertoli, Gloria ^a   Sanvito, Francesca ^b   Fusi, Paola ^c   Pagliarin, Roberto ^f   Orsini, Fulvia ^f   Moresco, Rosa Maria ^b,c   Coccetti, Paola ^c,d  

^a INSTITUTE OF MOLECULAR BIOIMAGING AND PHYSIOLOGY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d SYSBIO   (Italy)

^e Istovet Laboratories of Veterinary Histopathology   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

Azetidinones; Colorectal cancer; Combretastatin A4 (CA 4); PET; Xenograft

Indexed keywords

3-HYDROXY-4-(3-HYDROXY-4-METHOXYPHENYL)-1-(3,4,5-TRIMETHOXYPHENYL)AZETIDIN-2-ONE; ANTINEOPLASTIC AGENT; AZETIDINE DERIVATIVE; GLUCOSE; GUAIACOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CELL SURVIVAL; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; HUMAN; MALE; METABOLISM; MOUSE; PATHOLOGY; TUMOR CELL LINE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC AGENTS; AZETIDINES; CELL LINE, TUMOR; CELL SURVIVAL; COLORECTAL NEOPLASMS; GLUCOSE; GUAIACOL; HUMANS; MALE; MICE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938688375     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0148-8     Document Type: Article

References (37)

1. Boyle P, Zaridze DG, Smans M (1985) Descriptive epidemiology of colorectal cancer. Int J Cancer 36:9-18
2. G.T.W. W, David. Day, Jeremy R. Jass, Ashley B. Price, Neil A. Shepherd, James M. Sloan, Ian C. Talbot, Bryan F. Warren, Morson and Dawson's Gastrointestinal Pathology, Fourth Edition - Day - Wiley Online Library, (n.d.).
3. Venook A (2005) Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist 10:250-61
4. Houlston RS (2001) What we could do now: molecular pathology of colorectal cancer. Mol Pathol 54:206-14
5. Ilyas M, Straub J, Tomlinson IP, Bodmer WF (1999) Genetic pathways in colorectal and other cancers. Eur J Cancer 35:1986-2002
6. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759-67
7. Laurent-Puig P, Blons H, Cugnenc PH (1999) Sequence of molecular genetic events in colorectal tumorigenesis. Eur J Cancer Prev 8(Suppl 1):S39-47
8. Bardelli A, Siena S (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28:1254-61
9. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M et al (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97:1139-45
10. Nam N-H (2003) Combretastatin A-4 analogues as antimitotic antitumor agents. Curr Med Chem 10:1697-722
11. G.R. Pettit, C. Temple, V.L. Narayanan, R. Varma, M.J. Simpson, M.R. Boyd, et al., Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs., Anticancer. Drug Des. 10 (1995) 299-309.
12. Simoni D, Romagnoli R, Baruchello R, Rondanin R, Rizzi M, Pavani MG et al (2006) Novel combretastatin analogues endowed with antitumor activity. J Med Chem 49:3143-52
13. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC (1999) In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81:1318-27
14. West CML, Price P (2004) Combretastatin A4 phosphate. Anticancer Drugs 15:179-87
15. www.clinicaltrials.gov, (n.d.).
16. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57:1829-34
17. Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K et al (2005) Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 115:2992-3006
18. Mousset C, Giraud A, Provot O, Hamze A, Bignon J, Liu J-M et al (2008) Synthesis and antitumor activity of benzils related to combretastatin A-4. Bioorg Med Chem Lett 18:3266-71
19. F. Orsini, G. Sello, Bioactive Natural Products (Part N), Elsevier, 2008
20. Aprile S, Del Grosso E, Tron GC, Grosa G (2007) In vitro metabolism study of combretastatin A-4 in rat and human liver microsomes. Drug Metab Dispos 35:2252-61
21. Tripodi F, Pagliarin R, Fumagalli G, Bigi A, Fusi P, Orsini F et al (2012) Synthesis and biological evaluation of 1,4-diaryl-2-azetidinones as specific anticancer agents: activation of adenosine monophosphate activated protein kinase and induction of apoptosis. J Med Chem 55:2112-24
22. Hardie DG, Alessi DR (2013) LKB1 and AMPK and the cancer-metabolism link - ten years after. BMC Biol 11:36
23. Canta A, Chiorazzi A, Carozzi V, Meregalli C, Oggioni N, Sala B et al (2011) In vivo comparative study of the cytotoxicity of a liposomal formulation of cisplatin (lipoplatinTM). Cancer Chemother Pharmacol 68:1001-8
24. Meregalli C, Canta A, Carozzi VA, Chiorazzi A, Oggioni N, Gilardini A et al (2010) Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur J Pain 14:343-50
25. Motta A, Damiani C, Del Guerra A, Di Domenico G, Zavattini G (2002) Use of a fast EM algorithm for 3D image reconstruction with the YAP-PET tomograph. Comput Med Imaging Graph 26:293-302
26. Cavaletti G, Nicolini G, Marmiroli P (2008) Neurotoxic effects of antineoplastic drugs: the lesson of pre-clinical studies. Front Biosci 13:3506-24
27. Nabha SM, Mohammad RM, Wall NR, Dutcher JA, Salkini BM, Pettit GR et al (2001) Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy. Anticancer Drugs 12:57-63
28. Shen C-H, Shee J-J, Wu J-Y, Lin Y-W, Wu J-D, Liu Y-W (2010) Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model. Br J Pharmacol 160:2008-27
29. Thoeny HC, De Keyzer F, Chen F, Vandecaveye V, Verbeken EK, Ahmed B et al (2005) Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration. Neoplasia 7:779-87
30. Mur Blanch N, Chabot GG, Quentin L, Scherman D, Bourg S, Dauzonne D (2012) In vitro and in vivo biological evaluation of new 4,5-disubstituted 1,2,3-triazoles as cis-constrained analogs of combretastatin A4. Eur J Med Chem 54:22-32
31. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F et al (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67:6745-52
32. M. Zakikhani, R.J.O. Dowling, N. Sonenberg, M.N. Pollak, The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase., Cancer Prev. Res. (Phila). 1 (2008) 369-75.
33. J.R. Fay, V. Steele, J.A. Crowell, Energy homeostasis and cancer prevention: the AMP-activated protein kinase., Cancer Prev. Res. (Phila). 2 (2009) 301-9.
34. Warburg O (1956) On the origin of cancer cells. Science 123:309-14
35. Chiaradonna F, Moresco RM, Airoldi C, Gaglio D, Palorini R, Nicotra F et al (2012) From cancer metabolism to new biomarkers and drug targets. Biotechnol Adv 30:30-51
36. Zhao S (1999) J. V Moore, M.L. Waller, A.T. McGown, J.A. Hadfield, G.R. Pettit, et al., Positron emission tomography of murine liver metastases and the effects of treatment by combretastatin A-4. Eur J Nucl Med 26:231-8
37. Lankester KJ, Maxwell RJ, Pedley RB, Dearling JL, Qureshi UA, El-Emir E et al (2007) Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down. Int J Oncol 30:453-60